While controversy over Brexit reaches full boil, a pharma trade group sees the upside in a draft deal
British prime minister Theresa May’s draft divorce deal from the European Union has spurred hoots of derision from her growing ranks of critics in the UK, but the hard-fought and controversial agreement has met with cautious optimism from the trade association representing the biopharma and lifesciences industry in the United Kingdom.
The Association of the British Pharmaceutical Industry (ABPI), which represents biopharmaceutical companies in the UK that supply more than 80% of all branded medicines used by the National Health Service (NHS), said that although there was much work to be done, it welcomed the agreement of a transition period, which would mean its members can “continue to supply medicines to patients without delay or disruption come March 2019.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
